Evidence map›Paper›PMID 41577330›Full record

ReviewProgress in retinal and eye research2026

Aging, oxidative stress, and cataracts: Therapeutic prospects and translational insights into peroxiredoxin 6.

Eri Kubo, Bhavana Chhunchha, Dhirendra P Singh

Abstract readReview
In one paragraph

Review in Progress in retinal and eye research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Loss of Peroxiredoxin 6 Drives Age-Related Klf9/NF-Antioxidants (Basel, Switzerland) · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eri KuboDepartment of Ophthalmology, University of Kanazawa, 1-1 Daigaku, Kahoku-gin, Ishikawa, 920-0293, Japan. Electronic address: kuboe@kanazawa-med.ac.jp.
Bhavana ChhunchhaDepartment of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Dhirendra P SinghDepartment of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: dpsingh@unmc.edu.

Funding

Molecular approach to ameliorate the age-dependent loss of Clock protein Bmal1 and Nrf2-antioxidant response in eye lens: Implications for eye lens health spanR01EY036404 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DHIRENDRA P SINGH · 2025 to 2026
$769k
NEI NIH HHS R01 EY036404
6 · The paper itself

Abstract

Selenium-independent peroxiredoxin 6 (Prdx6) is a unique member of the peroxiredoxin family, which protects cells from various stressors by regulating reactive oxygen species (ROS) and maintaining survival signaling. As a multifunctional "moonlighting" protein, Prdx6 exhibits glutathione peroxidase (GPx), acidic calcium-independent phospholipase A2, and lysophosphatidylcholine acyltransferase activities, enabling it to reduce ROS. Loss of Prdx6, owing to dysregulation of its transactivator nuclear factor erythroid 2-related factor 2 or aberrant oxidative post-translational modifications from aging or oxidative stress, disrupts cellular homeostasis and triggers inflammatory or non-inflammatory cell death, including apoptosis and pyroptosis. Similar to GPx4, Prdx6 exhibits selenium-independent peroxidase activity and possesses phospholipid hydroperoxide-reducing GPx activity. A novel function of Prdx6 in facilitating selenium utilization was identified recently; that is, it enhances the expression and activity of selenoproteins, especially GPx4, and prevents ferroptosis. Conversely, Prdx6 deficiency reduces selenoprotein levels and promotes ferroptosis. Nevertheless, the molecular mechanisms through which Prdx6 modulates cell death and survival, particularly under aging and oxidative stress conditions contributing to cataractogenesis, remain unclear. In this review, we summarize the current knowledge of Prdx6 regulation and activity during oxidative stress and aging, highlighting its role in inflammatory and non-inflammatory signaling that contributes to eye lens pathology and cataract formation. Additionally, we discuss natural activators and potential therapeutic strategies targeting Prdx6 to extend eye lens health and delay or prevent cataract development. Overall, we conclude that enhancing Prdx6 activity offers a promising strategy to prevent or reverse age-related cataracts.

Indexed as

AgingCataractOxidative StressPeroxiredoxin VIAnimalsHumansReactive Oxygen SpeciesPeroxiredoxin VIReactive Oxygen SpeciesagingCataractogenesisDeath signalingInflammatory responseOxidative stressPeroxiredoxin 6Selenoproteins

Identifiers

PMID41577330
PMCPMC13041650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.